Behshad Sheldon Email & Phone Number

Princeton, Nj

Lund, Sweden

Princeton, New Jersey, United States

Philadelphia, Pennsylvania, United States

Princeton Nj

Princeton, New Jersey, United States

Princeton, New Jersey, United States

Princeton, Nj

Princeton, Nj

Princeton, Nj

Princeton, Nj

Member, Board of Directors, Otsuka Development & Commercialization, Inc. (2008 – 2012)(OPDC, Global development organization for Otsuka)• Fiduciary and risk management responsibilitieso Development project and budget reviewso Guidance for CEO on development strategieso Compliance, quality and HR policy approvals and oversight

Princeton, Nj

Global and US Marketing; Early development startegy; Corporate Communications; corporate planning, and stakeholder management.HIGHLIGHTED ACCOMPLISHMENTS• Co-founder of the Princeton office as the new US headquarters of Otsuka Pharmaceutical Co Ltd. o Number of employees grew from 3 to 180 over 10 yearso Member of management oversight committees at both the commercial and development organizations for Otsuka in the USo Member of Board of Directors for 2 Otsuka companies in the US and Canada• Key driver in partner selection and finalization of Nov 11, 2011 landmark agreement between Otsuka Pharmaceutical Co Ltd and Lundbeck on Abilify IM depot, brexpiprazole and 3 Lundbeck quids• Developed oncology franchise at Otsuka through the acquisition of Busulfex (BMT prep) and co-promotion agreement of Sprycel (CML) with BMS while extending and solidifying the CNS agreement with BMSo Leveraged CNS partnership with BMS to grow the Abilify business to over $6B in gross saleso Abilify now #1 antipsychotic in sales and # 3 product in entire US pharmaceutical market o Abilify has achieved 21% market share with 14 indications/formulations, despite having been the 6th atypical antipsychotic to launch• Alliance management with BMS, Lundbeck, GW Pharma, UCB • Successful launch in 2009 of Samsca (tolvaptan, vasopression antagonist for hyponatremia) o First-in-class product with significant market development needso Hospital product expected to reach >$100M in 2012 (third full year on market), originally forecasted to reach $35M at peak

Princeton, Nj

• Responsible for early development pipeline: driving development strategy to meet patient and physician needs • Global strategic integration for marketed products: building global brands that meet local needs• Alliance management with BMS and governance of Abilify • Driver of BMS 2008 agreement extension for Abilify, with the addition of oncology products Sprycel and Ixempra• Oversaw and guided the device division as part of the Medical Device Governance Committee

Princeton, Nj

• As member of Joint Commercialization Committee and Product Development Committees, drove the global launch plans for Abilify with BMS, including global pricing principle, forecasting and approval of local commercial resourcing plans• Otsuka-driven Abilify pediatric trials were optimized through matching of qualified sites with high patient population density geographies, leading to increased recruiting

• Led the prelaunch activities and launch strategy for Abilify, including positioning, messaging, targeting, resource allocation and medical education • Pricing principle and global launch sequence

Princeton, Nj

• Drove expansion strategy (combination with aspirin) and focused promotional message on symptoms vs long-term outcomes o 1999 sales increase of 277% vs 1998 to reach $543M; 2000 sales reached $903Mo Plavix sales peaked at >$6B

• Drove overall brand strategy and tactics including DTC• 1998 sales grew by 49% to $862M and went on to reach $1.3B in 99• First major DTC campaign in diabetes area• Glucophage brand sales peaked at to >$1.7BSenior Manager, Glucophage Promotions (1996 – 1997)

Product Manager, Timentin & BactrobanProduct Manager, BactrobanAPM, Amoxil and BactrobanRegional Marketing Consultant Sales Representative/Senior Sales Representative